Citadel Advisors’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

Citadel Advisors’s Portfolio RSLS Stock Details RSLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-796	Closed	-$5K	–	10197
2018 Q3	$5K	Buy	+796	New	+$68.5K	﹤0.01%	9132
2018 Q2	–	Sell	-9	Closed	-$28K	–	9575
2018 Q1	$28K	Buy	+9	New	+$28.6K	﹤0.01%	8069

Other funds holding RSLS

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Citadel Advisors's RSLS Position: Q4 2018 in Review

Citadel Advisors sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q4 2018, closing a stake of 796 shares — an estimated $5K sold.

Citadel Advisors first reported a position in RSLS in Q1 2018 and held it in 2 quarters. The position peaked at $28K in Q1 2018. 2 funds tracked by Wall St. Rank hold RSLS as of Q4 2018.

Citadel Advisors reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Citadel Advisors sold 796 ReShape Lifesciences Inc. Common Stock shares in Q4 2018, an estimated $5K.
Citadel Advisors first reported a position in ReShape Lifesciences Inc. Common Stock in Q1 2018 and held it in 2 quarters.
Citadel Advisors's ReShape Lifesciences Inc. Common Stock position peaked at $28K in Q1 2018.
2 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q4 2018.

Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.